尽管人乳头瘤病毒疫苗接种和筛查，但大约5%的宫颈癌（CC）是在初期转移阶段发现的。此外，近三分之一的局部晚期CC（LACC）患者在随访期间会出现疾病复发。在复发或转移性CC阶段，治疗选择非常有限。这些患者被认为是不可治愈的，预后非常差。多年来，标准治疗是铂类药物和紫杉醇的联合，并可能加用贝伐单抗。近年来，免疫检查点抑制剂（ICIs）（如pembrolizumab、cemiplimab等）在CC患者中的应用得到了发展。它们已经显示出1线治疗（与化疗联合）或2线治疗（作为单药治疗）对患者的长期反应和总体生存有所改善。另一种新兴的药物是tisotumab vedotin，一种靶向组织因子的抗体-药物偶联物。放射治疗（RT）通常在转移性癌症中具有有限的姑息治疗指示。然而，已观察到RT可以引起远离放射区域的远处转移肿瘤和原发肿瘤的肿瘤缩小。这是一种很少见的现象，称为全身效应，被认为与免疫系统有关，并且可以在全身产生肿瘤反应。这可能是由癌细胞的辐射诱导引起的免疫系统激活，导致特定类型的细胞凋亡，即致免疫性细胞死亡。目前，越来越多的人认为将RT与ICIs结合起来可能会提高各种癌症的全身效应或治愈率。在本文中，我们将回顾免疫辐射治疗在转移性宫颈癌中的潜在全身效应。© 2023 Ollivier, Moreau Bachelard, Renaud, Dhamelincourt and Lucia的版权。

Despite human papillomavirus vaccination and screening, in about 5% of cases, cervical cancer (CC) is discovered at an initial metastatic stage. Moreover, nearly one-third of patients with locally advanced CC (LACC) will have a recurrence of their disease during follow-up. At the stage of recurrent or metastatic CC, there are very few treatment options. They are considered incurable with a very poor prognosis. For many years, the standard of care was the combination of platinum-based drug and paclitaxel with the possible addition of bevacizumab. The most recent years have seen the development of the use of immune checkpoint inhibitors (ICIs) (pembrolizumab, cemiplimab and others) in patients with CC. They have shown long term responses with improved overall survival of patients in 1st line (in addition to chemotherapy) or 2nd line (as monotherapy) treatment. Another emerging drug is tisotumab vedotin, an antibody-drug conjugate targeting tissue factor. Radiation therapy (RT) often has a limited palliative indication in metastatic cancers. However, it has been observed that RT can induce tumor shrinkage both in distant metastatic tumors beyond the radiation field and in primary irradiated tumors. This is a rarely observed phenomenon, called abscopal effect, which is thought to be related to the immune system and allows a tumor response throughout the body. It would be the activation of the immune system induced by the irradiation of cancer cells that would lead to a specific type of apoptosis, the immunogenic cell death. Today, there is a growing consensus that combining RT with ICIs may boost abscopal response or cure rates for various cancers. Here we will review the potential abscopal effect of immune-radiation therapy in metastatic cervical cancer.Copyright © 2023 Ollivier, Moreau Bachelard, Renaud, Dhamelincourt and Lucia.